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bjectives The aim of this study was to evaluate the association between the length of the stented
egment and the risk of stent thrombosis (ST) after drug-eluting stent (DES) implantation and to
etermine the cutoff value of stent length in higher risk of ST in routine clinical practice.
ackground Despite the recommendations of full lesion coverage to prevent angiographic resteno-
is, the length of the stented segment has been a risk factor for DES-related ST.
ethods A total of 3,145 consecutive patients (4,667 lesions) who underwent DES implantation
ere analyzed. The independent association of stent length with ST and its predictive value were
valuated for a median 29.6 months (interquartile range 21.6 to 37.5 months).
esults Stent thrombosis occurred in 68 patients (2.2%) at 3 years. The stent length/lesion was an
ndependent predictor of ST (hazard ratio: 1.11, 95% conﬁdence interval: 1.06 to 1.15, p  0.001).
he threshold of stent length for predicting ST was 31.5 mm (area under the receiver-operating
haracteristic curve: 0.746, 95% conﬁdence interval: 0.699 to 0.793, p  0.001), which had a sensitiv-
ty and speciﬁcity of 88.4% and 52.1%, respectively. Stent lengths 31.5 mm were associated with
igher rates of ST (4.0% vs. 0.7%, p  0.001), death (5.2% vs. 3.0%, p  0.005), and myocardial in-
arction (2.4% vs. 0.7%, p  0.001) at 3 years, as compared with stent lengths 31.5 mm.
onclusions Length of the stented segment was independently associated with the incidence of ST
nd death or myocardial infarction after DES implantation. The value of stent length 31.5 mm is a
hreshold for the prediction of ST. (J Am Coll Cardiol Intv 2010;3:383–9) © 2010 by the American
ollege of Cardiology Foundation
rom the *Department of Cardiology, SoonChunHyang University Bucheon Hospital, University of SoonChunHyang College of
edicine, Bucheon, Korea; †Department of Cardiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul,
orea; and the ‡Department of Cardiology, University of Ulsan College of Medicine, Asan Medical Center, Gangneung, Korea.
his study was supported by the Cardiovascular Research Foundation (Korea) and a grant from the Korean Ministry of Health
nd Welfare as part of the Korea Health 21 Research and Development Project (0412-CR02-0704-0001).anuscript received October 21, 2009, accepted October 29, 2009.
U
a
r
(
D
m
l
t
(
w
l
b
o
s
t
s
t
t
C
d
i
1
c
(
e
w
r
e
c
S
t
n
p
f
D
a
t
w
l
c
o
p
d
D
c
H
u
l
C
c
[
c
p
e
o
o
6
m
d
r
i
fi
f
r
w
“
R
t
d
d
d
e
c
e
u
i
i
d
c
T
S
A
a
B
C
D
H
I
M
P
s
P
c
R
c
S
s
S
T
r
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 4 , 2 0 1 0
A P R I L 2 0 1 0 : 3 8 3 – 9
Suh et al.
Stent Length and Stent Thrombosis
384se of drug-eluting stents (DES) has significantly reduced
ngiographic restenosis rates and the need for subsequent
evascularization as compared with use of bare-metal stents
BMS) (1–3). Results from pivotal clinical trials show that
ES are widely used in routine clinical practice including
ore complex patients and lesion characteristics, and full
esion coverage by using a longer stent has been regarded as
he preferred strategy of percutaneous coronary intervention
PCI) to reduce the rate of restenosis. However, the
idespread use of DES has raised concerns regarding the
ong-term safety of late stent thrombosis (ST).
Several clinical, anatomic, and procedural factors have
een suggested to be important risk factors for development
f ST after DES implantation (4–9). Previous studies have
hown that the risk of ST is significantly associated with the
otal stent length (10,11). However, there have been limited
data regarding the prognostic
impact of DES length on ST
and clinical outcomes in “real-
world” use.
Therefore we evaluated the
independent relationship be-
tween stent length and the risk
of ST after DES implantation
and identified the threshold of
stent length for predicting in-
creased risk of ST and long-term
cardiovascular events.
Methods
Study population. The study in-
cluded 3,157 consecutive pa-
tients who underwent coronary
stent implantation with DES at
2 academic hospitals in Korea
between February 2003 and
February 2006. Drug-eluting
tents have been adopted as the default treatment for PCI
reatment since February, 2003, at the Asan Medical Cen-
er, Seoul, and since May, 2003, at the Asan Medical
enter, Gangneung.
Excluded from the analysis were patients with contrain-
ications to antiplatelet agents (i.e., active or major bleed-
ng), those requiring antiplatelet therapy interruption within
month after the procedure, and those who underwent
oronary brachytherapy. Thus, a total of 3,145 patients
4,667 lesions) were included in the analysis. Sirolimus-
luting stents (SES) and paclitaxel-eluting stents (PES)
ere used in 2,478 patients (79%) and 667 patients (21%),
espectively. The study was approved by the institutional
thics committee at each center, and written informed
bbreviations
nd Acronyms
MS  bare-metal stent(s)
I  confidence interval
ES  drug-eluting stent(s)
R  hazard ratio
QR  interquartile range
I  myocardial infarction
ES  paclitaxel-eluting
tent(s)
CI  percutaneous
oronary intervention
OC  receiver-operating
haracteristic
ES  sirolimus-eluting
tent(s)
T  stent thrombosis
LR  target lesion
evascularizationonsent was obtained. mtenting procedures and antiplatelet therapy. Stent implan-
ation was performed according to current standard tech-
iques. Primary PCI for the infarct-related culprit lesion for
atients with ST-segment elevation acute myocardial in-
arction (MI) was performed within 12 h of symptom onset.
uring the procedure, patients received intravenous weight-
djusted heparin treatment to achieve an activated clotting
ime of 300 s. The use of glycoprotein IIb/IIIa inhibitors
as at the physician’s discretion. All patients received a
oading dose of 100 to 200 mg aspirin and 300 or 600 mg
lopidogrel before or during PCI. After the procedure, 100
r 200 mg aspirin daily was continued indefinitely in all
atients. The prescription of at least 6 months of clopi-
ogrel 75 mg daily was recommended for patients receiving
ES irrespective of stent type. The duration of extended
lopidogrel use was determined at the physician’s discretion.
owever, the duration of prescribed clopidogrel was grad-
ally extended to at least 12 months after the concerns of
ate thrombosis had been raised (12).
linical follow-up and deﬁnitions. Clinical observation was
onducted for a median 29.6 months (interquartile range
IQR] 21.6 to 37.5). Information regarding baseline clinical
haracteristics, procedural data, and clinical events was
rospectively collected in an electronic database system by
xperienced research personnel who were unaware of the
bjective of the study. Post-discharge clinical data were
btained via regular outpatient visits with an interval of 3 or
months or telephone interview. To ensure detailed infor-
ation regarding clinical events during follow-up, survival
ata for all patients were obtained from the national
egistration system of the Ministry of Government Admin-
stration and Home Affairs in Korea with personal identi-
cation numbers. Also, data on repeat hospital stay for
ollow-up MI were obtained via the hospital disease code
egistration system, which was merged for reimbursement
ith the Health Insurance Review Agency in Korea.
The definition of ST corresponded to the levels of
definite,” “probable,” or “possible” proposed by Academic
esearch Consortium, and ST was classified on the basis of
he timing of the event as early (0 to 30 days), late (31 to 360
ays), or very late (360 days) according to standardized
efinitions (13,14). Death was defined as all-cause mortality
uring the follow-up period. The diagnosis of acute MI was
stablished in the presence of ischemic symptoms and
ardiac enzyme elevation (creatine kinase-myocardial band
levation3 times or creatine kinase elevation2 times the
pper limit of normal value) (15). Target lesion revascular-
zation (TLR) was defined as target lesion reintervention
nside the implanted stent or within 5 mm proximally or
istally by either PCI or bypass surgery. Major adverse
ardiac events were defined as a composite of death, MI, or
LR.
tatistical analysis. Continuous variables are presented as
ean  SD or median (IQR) and were compared with
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385tudent t test or Mann-Whitney U test. Categorical vari-
bles are presented as frequencies or percentages and were
ompared with chi-square or Fisher exact tests, as appro-
riate. Correlations between the incidence of ST and
ovariates were initially examined by use of univariate Cox
roportional hazards model. Variables with a p value 0.2
t univariate analysis and clinically relevant factors were
ntered in a multivariate Cox regression model with a
tepping algorithm to identify independent predictors of
T. A receiver-operating characteristic (ROC) curve anal-
sis with Youden index measure was performed to deter-
ine the best cutoff value of optimal stent length for
redicting the ST. Cumulative event curves were generated
ith the Kaplan–Meier method and compared with the
og-rank test of significance. All statistical tests were
-sided, and differences were considered statistically signif-
cant at p  0.05. Statistical analysis was performed with
PSS version 12.0 for windows (SPSS, Inc., Chicago,
llinois).
esults
ncidence of ST and clinical events. The study population
onsisted of 3,145 consecutive patients (treated for 4,667
esions) who received DES implantation (SES for 3,603
esions [77%] and PES for 1,064 lesions [23%]) between
Table 1. Baseline Clinical and Lesion Characteristics and Univariate Cox R
Variable
ST
(n  68)
Age, yrs 59.4 13.2
Male sex 51 (75.0)
Hypertension 36 (52.9)
Diabetes mellitus 22 (32.4)
Hypercholesterolemia 15 (22.1)
Current smoking 20 (30.3)
Previous myocardial infarction 8 (11.7)
Previous coronary angioplasty 10 (14.7)
Previous bypass surgery 3 (4.4)
Acute myocardial infarction 21 (30.9)
Renal failure 7 (10.3)
Left ventricular ejection fraction, % 52.9 11.4
Discontinuation of antiplatelet 6 months 16 (23.5)
Duration of antiplatelet therapy, months 11.5 8.8
Treated vessel and lesion characteristics
Left anterior descending 32 (46.4)
Left main 8 (11.6)
Chronic total occlusion 4 (5.8)
Restenotic lesion 7 (10.1)
Ostial lesion 7 (10.1)
Bifurcation lesion 14 (20.3)
ACC/AHA type B2 or C 53 (76.8)
Data represent mean SD for continuous variables and n (%) for dichotomous variables.ACC/AHA American College of Cardiology/American Heart Association; CI confidence interval; STebruary 2003 and February 2006. The median follow-up
uration was 29.6 months (IQR 21.6 to 37.5).
During the follow-up period, ST occurred in 68 patients
2.2%), and these were categorized as 27 definite, 7 proba-
le, and 34 possible. Early ST occurred in 9 patients (0.3%),
ate ST occurred in 28 patients (0.9%), and very late ST
ccurred in 31 patients (1.0%). The median time after the
rocedure was 4 days (IQR 2.0 to 9.3 days) for early ST
ccurrence, 7.0 months (IQR 4.6 to 8.5 months) for late
T, and 20.3 months (IQR 14.3 to 29.4 months) for very
ate ST. In ST patients, the mean duration of clopidogrel
se was 11.5  8.8 months. After discontinuation of
lopidogrel use, 21 (75.0%) patients developed late ST and
4 (77.4%) patients developed very late ST.
During follow-up, the cumulative incidence of major
dverse cardiac events at 3 years was 5.9%. Death occurred
n 4.2%, MI occurred in 1.6%, and TLR occurred in 2.7%
f patients. Of the 68 ST patients, 62% (42 of 68) died, 49%
33 of 68) had MI, and 38% (26 of 68) had TLR.
aseline characteristics. The baseline clinical and lesion
haracteristics comparing ST and non-ST patients as well as
orresponding results of univariate Cox proportional hazard
nalysis for ST development are presented in Table 1. The
T and non-ST patients were similar in terms of age, sex,
nd coronary risk factors, but ST patients had higher
sion Analysis
No ST
(n  3,077)
Univariate Hazard Ratio
(95% CI) p Value
60.6 10.2 0.99 (0.97–1.01) 0.40
2,166 (70.5) 1.23 (0.71–2.13) 0.46
1,534 (49.9) 1.13 (0.70–1.82) 0.61
834 (27.1) 1.29 (0.78–2.14) 0.33
679 (22.2) 0.98 (0.55–1.74) 0.94
871 (28.8) 1.04 (0.62–1.78) 0.88
307 (10.0) 2.51 (0.71–8.90) 0.28
521 (16.9) 0.81 (0.41–1.59) 0.54
82 (2.7) 1.74 (0.55–5.54) 0.35
336 (10.9) 3.79 (2.26–6.33) 0.001
36 (1.2) 8.06 (3.68–17.65) 0.001
58.7 8.7 0.95 (0.93–0.97) 0.001
294 (9.6) 2.71 (1.55–4.75) 0.001
13.0 9.4 0.98 (0.96–1.01) 0.14
2,265 (49.3) 0.81 (0.28–2.31) 0.69
317 (6.9) 1.43 (0.68–2.97) 0.34
252 (5.5) 0.85 (0.31–2.33) 0.75
327 (7.1) 1.12 (0.51–2.46) 0.77
375 (8.2) 1.20 (0.55–2.63) 0.64
743 (16.2) 0.99 (0.55–1.78) 0.96
3,861 (73.1) 1.51 (0.34–6.78) 0.59egresstent thrombosis.
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386ncidence of MI on presentation and renal failure and lower
eft ventricular ejection fraction than non-ST patients. Apart
rom the duration of antiplatelet therapy, discontinuation of
ntiplatelet therapy 6 months was more frequent in ST
atients than in non-ST patients. The angiographic and
rocedural findings according to ST are presented in Table 2.
he ST patients underwent more overlapping stents and
ore primary PCI and had more stents, longer stents, and
onger lesions than non-ST patients.
ndependent predictors of stent thrombosis. Stepwise mul-
ivariate Cox regression analysis showed that renal failure,
Table 2. Baseline Angiographic and Procedural Characteristics and Univari
Variable
ST
(n  68)
Multivessel PCI 16 (23.5)
Primary PCI 11 (16.1)
Bifurcation stenting 6 (8.7)
Direct stenting 8 (11.6)
Overlapping stenting 37 (54.4)
PCI with paclitaxel-eluting stent 18 (26.5)
Number of stents/lesion 1.7 0.9
Total stent length/lesion, mm 45.2 27.3
Number of stents/patient 2.2 1.5
Total stent length/patient, mm 57.3 42.1
Maximal balloon size, mm 3.7 0.4
Maximal balloon inﬂation, atm 15.8 4.3
Lesion length, mm 32.6 19.3
Reference vessel diameter, mm 3.0 0.4
Minimal luminal diameter, mm
Before intervention 0.9 0.6
After intervention 2.8 0.4
Diameter stenosis, %
Before intervention 68.1 19.3
After intervention 4.8 11.2
Acute gain, mm 1.9 0.5
Data represent mean SD for continuous variables and n (%) for dichotomous variables.
PCI percutaneous coronary intervention; other abbreviations as in Table 1.
Table 3. Independent Predictors of Stent Thrombosis
Variables
Hazard Ratio
(95% CI) p Value*
Overall stent thrombosis
Renal failure 7.97 (2.24–28.36) 0.001
Discontinuation of antiplatelet 6 months 2.77 (1.12–6.88) 0.028
Total stent length/lesion 1.11 (1.06–1.15) 0.001
Very late stent thrombosis
Left ventricular ejection fraction 0.95 (0.91–1.00) 0.035
Total stent length/lesion 1.15 (1.05–1.25) 0.001
Diameter stenosis, post 3.23 (1.42–7.42) 0.006
*Predictors with a p value  0.2 were entered into multivariate Cox-regression analysis with a
stepping algorithm.Abbreviations as in Table 1.iscontinuation of antiplatelet 6 months, and total stent
ength/lesion were independent risk factors of ST (Table 3).
eft ventricular ejection fraction and total stent length/
esion were major predictors of very late ST. Of the
rocedural variables, total stent length/lesion was the only
Figure 1. Receiver-Operating Characteristic Curve
A receiver-operating characteristic curve to identify optimal stent length for
predicting stent thrombosis. The number on the curve represents the best
ox Regression Analysis
o ST
3,077)
Univariate Hazard Ratio
(95% CI) p Value
4 (33.6) 0.59 (0.34–1.04) 0.07
9 (7.7) 2.54 (1.33–4.87) 0.005
4 (4.9) 1.42 (0.61–3.28) 0.41
9 (17.0) 0.81 (0.39–1.69) 0.57
4 (26.8) 2.18 (1.36–3.50) 0.01
9 (21.1) 0.77 (0.45–1.31) 0.33
 0.6 1.71 (1.32–2.20) 0.001
 18.8 1.02 (1.01–1.03) 0.001
 1.1 1.18 (0.97–1.41) 0.06
 35.6 1.01 (1.00–1.02) 0.001
 0.6 1.07 (0.81–1.43) 0.63
 3.9 0.98 (0.93–1.04) 0.56
 14.6 1.02 (1.00–1.03) 0.03
 0.5 1.18 (0.68–2.06) 0.55
 0.5 1.04 (0.67–1.60) 0.87
 0.5 0.90 (0.52–1.54) 0.69
 17.6 1.00 (0.98–1.02) 0.75
 13.4 1.02 (0.99–1.04) 0.17
 0.6 0.77 (0.44–1.33) 0.35ate C
N
(n 
1,03
23
22
75
1,23
64
1.4
34.2
1.9
56.9
3.6
15.9
26.2
2.9
0.9
2.8
67.6
1.9
1.9predictive value of optimal stent length. CI  conﬁdence interval.
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387redictor of ST (hazard ratio [HR]: 1.11, 95% confidence
nterval [CI]: 1.06 to 1.15, p  0.001).
tent length as a predictor of ST. An ROC curve to deter-
ine the cutoff value of stent length for predicting ST
ccurrence is shown in Figure 1. The area under the curve
as 0.746 (95% CI: 0.699 to 0.793, p  0.001), showing
air discrimination, and the stent length that best predicted
T was 31.5 mm. In the present study, 1,761 (56%) patients
ad stents longer than 31.5 mm. Patients with stent lengths
31.5 mm had a higher 3-year cumulative ST incidence
ate compared with patients with stent lengths 31.5 mm
4.0% vs. 0.7%, [log rank] p  0.001) (Fig. 2A). Adjusted
ox regression analysis showed that stent lengths 31.5
m were accompanied by an increased risk of ST (HR:
.87, 95% CI: 2.57 to 24.17, p  0.001) (Fig. 3).
Stent lengths 31.5 mm predicted ST with a sensitivity
f 88.4% and a specificity of 52.1%.
elationship between stent length and clinical outcomes.
Figure 2. Kaplan-Meier Curves of 3-Year Cumulative Incidence of Clinical O
Comparison of 3-year cumulative adverse outcomes according to the optimal
cardial infarction (MI), (D) death/myocardial infarction.he 3-year cumulative clinical outcomes according to the
tent length prediction value are depicted in Figure 2. The
-year mortality was higher in patients with stent lengths
31.5 mm as compared with those with stent lengths
31.5 mm (5.2% vs. 3.0%, [log rank] p  0.005) (Fig. 2B).
he 3-year follow-up MI rate was also higher in patients
ith stent lengths 31.5 mm compared with those with
tent lengths 31.5 mm (2.4% vs. 0.7%, [log rank] p 
.001) (Fig. 2C). Accordingly, patients with stent lengths
31.5 mm had a higher association with overall rate of
eath or MI, compared with those with stent lengths31.5
m (6.9% vs. 3.5%, [log rank] p  0.001) (Fig. 2D).
iscussion
he main finding of the present study was that longer stent
engths were significantly associated with a higher risk of ST
nd major coronary events (i.e., cardiac death and MI) in
es
tive stent length of 31.5 mm. (A) Stent thrombosis (ST), (B) death, (C) myo-utcom
predic
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388atients who received DES implantation. In addition, the
alue of 31.5 mm is a threshold above which there is a
igher likelihood of ST with a sensitivity and specificity of
8% and 52%, respectively. Hence, patients with stent
engths 31.5 mm had a higher cumulative incidence rate
f ST, death, and MI as compared with those with stent
engths 31.5 mm.
tent length as a predictor of ST and clinical events. The
ncreased off-label use of DES has raised issues regarding
ow to manage complex lesions in terms of complete
evascularization. Use of multiple or longer stents for
omplex intervention increases the risk of ST, regardless of
he presence or absence of conventional ST risk. However, the
ong-term clinical impact of stent length on ST development
n the DES era remains to be determined. Previous studies
howed that ST incidence after BMS implantation was related
o stent length (16). Similarly, recent reports also showed an
ssociation between stent length and increased clinical risk of
T after DES implantation (11,17,18).
A major finding of the present study was that stent
ength/lesion was the most important procedure-related risk
actor for development of ST during long-term follow-up.
his result is consistent with the ARTS II (Arterial Revas-
ularization Therapies Study Part II) analysis, showing that
otal stent length was an independent predictor of ST at 3
ears (HR: 1.14, 95% CI: 1.04 to 1.25, p 0.0037) (17,19).
lthough the present study had a lower-risk procedural
rofile than for the ARTS II analysis, total stented length
as also found to be an independent predictor of ST in the
urrent study. Moreover, in the current study, the threshold
f predictive stent length was found to be 31.5 mm, with
Figure 3. Adjusted Cox Regression Analysis
Adjusted cumulative hazard ratio (HR) of stent thrombosis (ST) up to 3
years according to the optimal predictive stent length of 31.5 mm. Abbre-
viations as in Figure 1.tents longer than 31.5 mm associated with a remarkablyigher risk of ST. Indeed, of the 68 ST patients, 60 (88%)
ad stent lengths/lesion longer than 31.5 mm.
Another major finding of this study was that the inci-
ence of death or MI was significantly proportional to stent
ength. The incidence of adverse clinical events associated
ith long DES in the present study was lower than that
eported to be associated with BMS (20,21). These were
eassuring results compared with previous BMS studies
howing a positive association between stent length and
dverse cardiac events (22).
Although the long DES seem to be safer and more
ffective than BMS, to date, data regarding DES length and
dverse events are lacking. It seems that the present findings
howing an association between stent length and coronary
vents after implantation should be considered when assess-
ng safety relating to DES use.
tudy limitations. Although all variables were included by
ackward elimination step-wise manner in multivariable
nalysis, there are too many candidate variables for the
ultivariable Cox models, given the number of end points.
ncluding death, there are competing events that might
nterfere with the ST event risk. The present report de-
cribes an observational study from 2 centers. The associa-
ion between ST risk and stent length in terms of DES type
as not evaluated. Also, mostly SES were used in this study.
herefore, it was a nonrandomized study design, and the
rocedures used were those recommended by each institu-
ion. Furthermore, the lack of procedure-supported intra-
ascular ultrasound data evaluation diminished the power of
he study to show the effectiveness of DES procedures.
owever, we performed PCI with intravascular ultrasound
uidance in more than approximately 70% of patients,
ecause such a procedure is likely of clinical benefit.
onclusions
he present study demonstrated that stent length is an
ndependent predictor of ST after DES implantation. The
isk of ST as well as death or MI was higher if the stented
egment was 31.5 mm long. Therefore, longer stent
ength was related to greater risk of ST, death, and MI after
ES implantation.
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